Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Mounjaro KwikPen is a pre-filled, single-use injection device containing tirzepatide — Eli Lilly's once-weekly weight-management medicine. Each pen holds four weekly doses and is designed so that a prepared injector requires no manual needle attachment and delivers the medicine with a single click. It is a prescription-only medicine; a prescriber assesses whether it is clinically suitable for you before any supply. Here is exactly what to expect when the pen arrives and how to use it correctly.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Your pen arrives by tracked DPD in plain, unbranded packaging, along with a small pouch of four needles. Before you do anything else, check the label: the strength printed on the pen should match what your prescriber confirmed at your last clinical review. Then hold the pen up to the light and look through the clear window. The liquid should be colourless or very faintly yellow and free of particles. If it looks cloudy, discoloured or contains visible debris, do not use it, contact your prescriber.
Take the pen out of the fridge around 30 minutes before you plan to inject. Cold medicine at the tip of the needle can sting more than medicine at room temperature. While you wait, wash your hands thoroughly. Gather what you need: the pen, a fresh needle from the pack, a clean alcohol swab if you have one, and a sharps disposal container to put the used needle in safely. Disposing of needles in household bins is unsafe and illegal; a dedicated sharps container is the right way to handle them.
The needles supplied with the KwikPen are for single use only. Reusing a needle blunts the tip, increases injection discomfort and raises the risk of contamination. One fresh needle per dose, every time.
Peel the outer wrapper from a new needle and screw it clockwise onto the needle thread at the top of the pen until it is snug. Do not overtighten, firm is enough. Remove the outer needle cap and keep it: you will need it to remove the needle afterwards. Then remove the inner needle cap and discard it.
The KwikPen does not require a traditional priming step in the way some older insulin pens do; the device is pre-primed by the manufacturer. What you should do is check the dose counter window to confirm the pen is set at the correct position before injecting. The detailed KwikPen instructions from the Patient Information Leaflet walk through the counter window checks in full, it is worth reading them at least once before your first injection, even if the steps feel intuitive.
Select your injection site for this week. If you used your abdomen last week, move to the thigh or upper arm now. Clean the skin with an alcohol swab if you are using one, and allow it to dry completely, injecting into damp skin can sting and the alcohol can interfere slightly with absorption. According to the NHS patient guide to tirzepatide, rotating sites consistently is one of the simplest ways to reduce injection-site reactions over time.
Pinch a small fold of skin gently at the site, place the pen flat against it, and press the injection button firmly. You will hear a click. Keep the pen pressed against the skin until the dose counter returns to zero, this usually takes around ten seconds. Do not lift the pen early; removing it before the counter reaches zero risks delivering an incomplete dose.
Once the counter shows zero, lift the pen away. Some people notice a tiny drop of liquid on the skin surface; this is not a sign that the dose was missed. A small amount of redness or slight bruising at the site is normal and typically fades within a day or two. If you experience significant pain, swelling or hardness that does not settle, let your prescriber know.
Immediately replace the outer needle cap on the used needle (use the one-handed scoop technique to avoid a needlestick injury) then unscrew the needle and place it straight into your sharps bin. Recap the pen, return it to the fridge, and record the day you injected. Keeping a simple note of the day prevents accidental double-dosing or a missed week. If you want to understand more about how each tirzepatide injection works physiologically, we have covered that in more detail elsewhere.
The most commonly reported side effects with tirzepatide are gastrointestinal: nausea, loose stools, constipation, burping and indigestion. These tend to be most noticeable in the first week or two after starting or after a dose increase, and they settle for most people as the body adjusts. Eating smaller portions, avoiding fatty or very spicy food, and staying well hydrated are the most consistently useful practical measures.
Two situations require you to seek urgent medical attention rather than wait. First, if you develop severe abdominal pain that radiates towards the back, with or without vomiting, this may indicate pancreatitis, the MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and you should not manage that symptom at home. Second, signs of a serious allergic reaction (throat tightening, widespread rash, difficulty breathing) need emergency care immediately.
For a broader picture of what clinical trial participants experienced, the NICE technology appraisal for tirzepatide (TA1026) summarises the safety evidence used to support its UK recommendation. If you have questions about a specific symptom between doses, our aftercare team is available seven days a week and will connect you with a prescriber where needed. For those weighing up whether this treatment is right for them, understanding the cost structure of private treatment is a natural next step before starting a free consultation.
Tirzepatide is not recommended during pregnancy, breastfeeding or when actively trying to conceive, and it is not licensed for anyone under 18. Women taking oral contraceptives should use an additional non-oral method for the first four weeks of treatment and for four weeks after any dose increase, because the medicine's effect on gastric emptying can reduce pill absorption, switching to patches or another non-oral method removes that uncertainty entirely.
If you are ready to explore whether Mounjaro is available as a KwikPen or prefer to review how the standard Mounjaro pen works before deciding, both options are covered in detail to help you choose confidently, and checking your eligibility with our prescribers is free, with a qualified clinician reading every response the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.